DK1242115T3 - Kemisk programmerbar immunitet - Google Patents

Kemisk programmerbar immunitet

Info

Publication number
DK1242115T3
DK1242115T3 DK00990960T DK00990960T DK1242115T3 DK 1242115 T3 DK1242115 T3 DK 1242115T3 DK 00990960 T DK00990960 T DK 00990960T DK 00990960 T DK00990960 T DK 00990960T DK 1242115 T3 DK1242115 T3 DK 1242115T3
Authority
DK
Denmark
Prior art keywords
molecule
binding site
immunity
human
sites
Prior art date
Application number
DK00990960T
Other languages
English (en)
Inventor
Kary B Mullis
Original Assignee
Kary B Mullis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kary B Mullis filed Critical Kary B Mullis
Application granted granted Critical
Publication of DK1242115T3 publication Critical patent/DK1242115T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Residential Or Office Buildings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00990960T 1999-12-22 2000-12-21 Kemisk programmerbar immunitet DK1242115T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17170799P 1999-12-22 1999-12-22
PCT/US2000/035179 WO2001045734A1 (en) 1999-12-22 2000-12-21 Chemically-programmable immunity

Publications (1)

Publication Number Publication Date
DK1242115T3 true DK1242115T3 (da) 2009-10-05

Family

ID=22624828

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00990960T DK1242115T3 (da) 1999-12-22 2000-12-21 Kemisk programmerbar immunitet

Country Status (9)

Country Link
US (5) US20030017165A1 (da)
EP (1) EP1242115B1 (da)
AT (1) ATE433327T1 (da)
AU (1) AU3076601A (da)
CA (1) CA2328356A1 (da)
DE (1) DE60042369D1 (da)
DK (1) DK1242115T3 (da)
ES (1) ES2328102T3 (da)
WO (1) WO2001045734A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2328356A1 (en) 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
US7645743B2 (en) 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
EP1594898A2 (en) 2003-02-06 2005-11-16 Tripep AB Glycosylated specificity exchangers
US7440877B2 (en) * 2004-03-12 2008-10-21 General Motors Corporation System and method for morphable model design space definition
US20070134259A1 (en) * 2005-11-21 2007-06-14 David Bundle Methods and compositions for pharmacologially controlled targeted immunotherapy
EP1790358A1 (en) 2005-11-23 2007-05-30 Université de Reims Champagne-Ardennes Protein constructs designed for targeting and lysis of cells
US20100166695A1 (en) * 2007-03-23 2010-07-01 The Governors Of The University Of Alberta Multivalent Heterobifunctional Polymers And Methods Of Their Use
CA2760774A1 (en) * 2009-05-05 2010-11-11 Altermune Technologies, Llc Chemically programmable immunity
MA45468A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques myc et utilisations
MA45470A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques kras et leurs utilisations
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
MA45471A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de phosphatidylinositol-3-kinase et leurs utilisations
MA45349A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques egfr et leurs utilisations
MA45469A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de bêta-caténine et leurs utilisations
CN110381980A (zh) 2017-01-06 2019-10-25 艾维迪提生物科学有限责任公司 核酸-多肽组合物以及诱导外显子跳读的方法
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
AU2018346507A1 (en) 2017-10-04 2020-04-23 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
AU2018378812A1 (en) 2017-12-06 2020-07-09 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
EP3898693A4 (en) 2018-12-21 2022-09-21 Avidity Biosciences, Inc. ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF
GB201904534D0 (en) 2019-04-01 2019-05-15 Centauri Therapeutics Ltd Novel compounds an therapeutic uses thereof
AU2020289464A1 (en) 2019-06-06 2022-01-20 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
CA3142337A1 (en) 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Una amidites and uses thereof
TW202144572A (zh) 2020-03-19 2021-12-01 美商亞維代堤生物科學公司 治療臉肩胛肱骨肌肉失養症之組合物及方法
EP4126066A4 (en) 2020-03-27 2024-04-24 Avidity Biosciences, Inc. COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHY
CA3231330A1 (en) 2021-09-16 2023-03-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169137A (en) * 1974-12-20 1979-09-25 Block Engineering, Inc. Antigen detecting reagents
IL51667A (en) * 1977-03-16 1979-10-31 Miles Yeda Ltd Immunoassay for the determination of a hapten
US5017558A (en) * 1980-01-14 1991-05-21 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
US4711955A (en) * 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US4737453A (en) * 1984-12-12 1988-04-12 Immunomedics, Inc. Sandwich immunoassay utilizing a separation specific binding substance
US4637459A (en) * 1985-06-28 1987-01-20 Roussel Louis J Anti rotational device for down hole hydraulic pumping unit
US4940670A (en) * 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
DK8189A (da) * 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
US5378815A (en) * 1989-10-20 1995-01-03 National Research Council Canada Process for indirect targeted immunocytolysis
GB8924438D0 (en) 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
US5218088A (en) 1989-11-02 1993-06-08 Purdue Research Foundation Process for preparing dithiophosphate oligonucleotide analogs via nucleoside thiophosphoramidite intermediates
US6344321B1 (en) 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US5962219A (en) 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US6331394B1 (en) 1991-06-10 2001-12-18 Gilead Sciences, Inc. Nucleic acid ligands to integrins
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
ATE160821T1 (de) * 1990-06-11 1997-12-15 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
AU9053991A (en) 1990-11-20 1992-06-11 Tanox Biosystems, Inc. Conjugates of anti-idiotype antibodies and carriers and their use in epitope-directed immunization
WO1995005454A1 (en) 1992-02-22 1995-02-23 Cambridge Bacteriophage Technologies Ltd. Engineered bacteriophages and vaccines containing them
US6579696B1 (en) * 1992-12-21 2003-06-17 Promega Corporation Polymyxin B conjugates
SE9401460D0 (sv) * 1994-04-28 1994-04-28 Ferring Ab Antigen/antibody specificity exhanger
US6040137A (en) * 1995-04-27 2000-03-21 Tripep Ab Antigen/antibody specification exchanger
US6933366B2 (en) * 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US6660842B1 (en) * 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
EP0833666B1 (en) * 1996-04-10 2003-12-10 Sangstat Medical Corporation Cytomodulating conjugates of members of specific binding pairs
EP1007569B1 (en) 1997-02-11 2009-04-08 Immunomedics, Inc. Stimulation of an immune response with antibodies labeled with the alpha-galactosyl epitope
US6140091A (en) * 1997-06-20 2000-10-31 Boston Biomedical Research Institute Anti-idiotype vaccines to elicit catalytic antibodies
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
US7112328B2 (en) * 1998-07-16 2006-09-26 Vincent Marinkovich Composition for targeted cell treatment
US6423493B1 (en) 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
WO2001032207A1 (en) * 1998-10-30 2001-05-10 United States Army Medical Research And Materiel Command Methods for conferring active/passive immunotherapy
US6329145B1 (en) 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
US6280943B1 (en) 1999-06-17 2001-08-28 Gilead Sciences, Inc. 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands
US6387620B1 (en) 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
EP1088889A1 (en) 1999-10-01 2001-04-04 University Of Cambridge Recombinant double hybrid filamentous bacteriophage
JP2003514828A (ja) 1999-10-27 2003-04-22 セル−サイ・コーポレーシヨン 自己免疫および移植組織に関連する宿主対移植片症状の処置に有用なペプチド構築物の調製法および組成物
US7645743B2 (en) 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
CA2328356A1 (en) 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
JP5059271B2 (ja) * 2000-03-31 2012-10-24 パーデュー・リサーチ・ファウンデイション リガンド免疫原複合体を用いる処置方法
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs

Also Published As

Publication number Publication date
EP1242115A1 (en) 2002-09-25
ATE433327T1 (de) 2009-06-15
US7422746B2 (en) 2008-09-09
US7850975B2 (en) 2010-12-14
DE60042369D1 (de) 2009-07-23
US20090142368A1 (en) 2009-06-04
US20040146515A1 (en) 2004-07-29
WO2001045734A1 (en) 2001-06-28
EP1242115A4 (en) 2004-06-16
US20070148183A1 (en) 2007-06-28
US20030017165A1 (en) 2003-01-23
AU3076601A (en) 2001-07-03
US8236321B2 (en) 2012-08-07
CA2328356A1 (en) 2001-06-22
ES2328102T3 (es) 2009-11-10
US8591910B2 (en) 2013-11-26
EP1242115B1 (en) 2009-06-10
US20120276136A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
DK1242115T3 (da) Kemisk programmerbar immunitet
DE69830326D1 (de) Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel
DE60130256D1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
WO2004010957A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
DE60142342D1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
WO2003043583A3 (en) Treatment of immunological disorders using anti-cd30 antibodies
AU9399501A (en) Therapeutic antibodies
ATE473759T1 (de) Bifunktionelle moleküle sowie darauf basierende therapien.
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
AU2002364954A1 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
ATE198834T1 (de) Konjugate bestehend aus polysaccharid und protein
ATE505208T1 (de) Rezeptorbindende konjugate
WO2005079423A3 (en) Chemically programmable immunity
DE69826684D1 (de) Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendungen
ATE355288T1 (de) Verbindungen und therapeutische methoden
DK1327146T3 (da) Forbindelse med et forgrenet linkermolekyle
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
GB9921592D0 (en) Preparation of highly pure toxin fragments
ATE232081T1 (de) Orale zusammensetzung enthaltend perlit
NO20021573D0 (no) Tverrbundne kopolymerer basert på ikke-tverrbundne polykarboksylkopolymerer
EA200000531A1 (ru) Применение кетолидов для профилактики тромботических артериальных осложнений, связанных с атеросклерозом
ID27733A (id) Metoksiminofenilasetamida
FI961339A (fi) Triaryylieteenijohdannaiset käytettäväksi hoidossa